Related Experiment Video
Updated: May 26, 2026
11:27
A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
IκB kinase alpha and cancer.
Shuang Liu1, Zhisong Chen, Feng Zhu
1Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.
Summary
IκB kinase alpha (IKK-α) acts as a tumor suppressor in squamous cell carcinomas (SCCs). Loss of IKK-α promotes skin tumor initiation and progression, offering potential therapeutic targets for SCC treatment.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Squamous cell carcinomas (SCCs) are common skin cancers.
- Mutations and downregulation of IκB kinase alpha (IKK-α) are observed in human SCCs.
- IKK-α is crucial in keratinocyte biology.
Purpose of the Study:
- To investigate the role of IKK-α in skin tumor development.
- To elucidate the molecular mechanisms underlying IKK-α's function in SCCs.
- To explore IKK-α as a potential therapeutic target for SCCs.
Main Methods:
- Analysis of IKK-α gene mutations and expression in human SCCs.
- Chemical skin carcinogenesis models in mice to study tumor initiation and progression.
- Inducible deletion of IKK-α in mouse keratinocytes.
Main Results:
- Reduced IKK-α expression promotes SCC tumor initiation.
- Loss of IKK-α significantly enhances tumor progression from benign to malignant stages.
- Inducible deletion of IKK-α in mice leads to spontaneous skin papillomas and carcinomas.
Conclusions:
- IKK-α functions as a tumor suppressor in SCC development.
- IKK-α plays dual roles as a tumor initiator and promoter in skin carcinogenesis.
- Understanding IKK-α's activity may lead to new strategies for SCC diagnosis, treatment, and prevention.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...